



**TABLE S1.** Strains used in this study.

Strain	Parent	Genotype or description	Reference
SM1		Azole-susceptible clinical isolate	(1)
SM3		Azole-resistant clinical isolate	(1)
SM1RPDR1(SM3)	SM1 $\Delta$ <i>pdr1</i>	<i>pdr1</i> $\Delta$ :: <i>FRT-PDR1</i> <sup>SM3</sup>	(2)
SM1 $\Delta$ <i>pdr1</i>	SM1	<i>pdr1</i> $\Delta$ :: <i>FRT</i>	(2)
SM3 $\Delta$ <i>pdr1</i>	SM3	<i>pdr1</i> $\Delta$ :: <i>FRT</i>	This study
S1RPS3CDR1M2A	SM1RPDR1(SM3)	<i>pdr1</i> $\Delta$ :: <i>FRT-PDR1</i> <sup>SM3</sup> / <i>cdr1</i> $\Delta$ :: <i>FRT</i>	(3)
S1RPS3PDH1M2A	SM1RPDR1(SM3)	<i>pdr1</i> $\Delta$ :: <i>FRT-PDR1</i> <sup>SM3</sup> / <i>pdh1</i> $\Delta$ :: <i>FRT</i>	(3)
S1RPS3SNQ2M2A	SM1RPDR1(SM3)	<i>pdr1</i> $\Delta$ :: <i>FRT-PDR1</i> <sup>SM3</sup> / <i>snq2</i> $\Delta$ :: <i>FRT</i>	(3)
S1RPS3CAPDH1M2A	S1RPS3CDR1M2A	<i>pdr1</i> $\Delta$ :: <i>FRT-PDR1</i> <sup>SM3</sup> / <i>cdr1</i> $\Delta$ :: <i>FRT</i> / <i>pdh1</i> $\Delta$ :: <i>FRT</i>	(3)
S1RPS3CASNQ2M2A	S1RPS3CDR1M2Q	<i>pdr1</i> $\Delta$ :: <i>FRT-PDR1</i> <sup>SM3</sup> / <i>cdr1</i> $\Delta$ :: <i>FRT</i> / <i>snq2</i> $\Delta$ :: <i>FRT</i>	(3)
S1RPS3SAPDH1M2A	S1RPS3SNQ2M2A	<i>pdr1</i> $\Delta$ :: <i>FRT-PDR1</i> <sup>SM3</sup> / <i>pdh1</i> $\Delta$ :: <i>FRT</i> / <i>snq2</i> $\Delta$ :: <i>FRT</i>	(3)
S1RPS3CAPASNQ2M2A	S1RPS3CAPDH1M2A	<i>pdr1</i> $\Delta$ :: <i>FRT-PDR1</i> <sup>SM3</sup> / <i>cdr1</i> $\Delta$ :: <i>FRT</i> / <i>pdh1</i> $\Delta$ :: <i>FRT</i> / <i>snq2</i> $\Delta$ :: <i>FRT</i>	(3)
SM1 $\Delta$ <i>upc2A</i>	SM1	<i>upc2A</i> $\Delta$ :: <i>FRT</i>	(4)
SM3 $\Delta$ <i>upc2A</i>	SM3	<i>upc2A</i> $\Delta$ :: <i>FRT</i>	(4)



**FIGURE S1.** 24-hour CLSI MIC comparison of matched clinical isolates SM1 and SM3 for VT-1161, VT-1598, fluconazole, itraconazole, posaconazole, and voriconazole.



**FIGURE S2.** 24- hour CLSI MIC comparison of the  $\Delta cdr1\Delta pdh1$  double deletion strain S1RPS3CAPDH1M2A, the  $\Delta cdr1\Delta snq2$  deletion strain S1RPS3CASNQ2M2A, the  $\Delta pdh1\Delta snq2$  deletion strain S1RPS3SAPDH1M2A, and the  $\Delta cdr1\Delta pdh1\Delta snq2$  triple deletion strain S1RPS3CAPASNQ2M2A compared to SM1 and SM1RPDR1(SM3) for VT-1161, VT-1598, fluconazole, itraconazole, posaconazole, and voriconazole. Strain SM1RPDR1(SM3) is an SM1 derivative in which the *PDR1* ORF of SM1 was replaced with the *PDR1* ORF of SM3.

## REFERENCES

1. Magill SS, Shields C, Sears CL, Choti M, Merz WG. 2006. Triazole cross-resistance among *Candida* spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. *J Clin Microbiol* 44:529-35.
2. Caudle KE, Barker KS, Wiederhold NP, Xu L, Homayouni R, Rogers PD. 2011. Genomewide expression profile analysis of the *Candida glabrata* Pdr1 regulon. *Eukaryot Cell* 10:373-83.
3. Whaley SG, Zhang Q, Caudle KE, Rogers PD. 2018. Relative Contribution of the ABC Transporters Cdr1, Pdh1, and Snq2 to Azole Resistance in *Candida glabrata*. *Antimicrob Agents Chemother* 62:e01070-18.
4. Whaley SG, Caudle KE, Vermitsky JP, Chadwick SG, Toner G, Barker KS, Gygax SE, Rogers PD. 2014. UPC2A is required for high-level azole antifungal resistance in *Candida glabrata*. *Antimicrob Agents Chemother* 58:4543-54.